Basic mechanisms and clinical implications of peritoneal fibrosis.
about
The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal MetastasisMesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal DialysisThe effect of statin on epithelial-mesenchymal transition in peritoneal mesothelial cells.Periostin: a matricellular protein involved in peritoneal injury during peritoneal dialysis.Fibrin-Induced epithelial-to-mesenchymal transition of peritoneal mesothelial cells as a mechanism of peritoneal fibrosis: effects of pentoxifyllinePatients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-β1, and vascular endothelial growth factor.Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transitionTamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.A pathogenetic role for endothelin-1 in peritoneal dialysis-associated fibrosisEncapsulating peritoneal sclerosis-a rare but devastating peritoneal disease.Transition of mesothelial cell to fibroblast in peritoneal dialysis: EMT, stem cell or bystander?Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damagePathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells.Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells.Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT.Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cellsThe Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis.Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signalingNebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.Genomic reprograming analysis of the Mesothelial to Mesenchymal Transition identifies biomarkers in peritoneal dialysis patientsImpact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology.The Role of Tyrosine Kinase Receptors in Peritoneal FibrosisEffluent markers related to epithelial mesenchymal transition with adjusted values for effluent cancer antigen 125 in peritoneal dialysis patients.Peritoneal Dialysis Catheter Increases Leukocyte Recruitment in the Mouse Parietal Peritoneum Microcirculation and Causes Fibrosis.RhoA/Rho-kinase triggers epithelial-mesenchymal transition in mesothelial cells and contributes to the pathogenesis of dialysis-related peritoneal fibrosis.
P2860
Q26783022-BBA5526E-BFDA-43CA-81A7-55D846D69F54Q28390104-0C304665-383E-49D1-A56E-4D64E46FDEF3Q34282610-A43EA0E6-D7FC-4836-92FF-F4438B1DA791Q34326012-64B4117A-FA0C-43D5-9BD6-1E40CAA69078Q34427394-0618BB40-836C-44FF-BCE2-F5B2F3138A53Q34482573-4611BE14-FC33-44CB-932D-ED67AF8D30BCQ34667822-E5988FDD-BEAB-4473-A921-9188A2F7C059Q34700117-77FB6146-E573-4BC3-A39A-0C48E11B1F79Q34787745-AC3D9746-3021-4FDE-AEB6-D611E5ABE10AQ34816520-D8A55160-8DE0-43D5-92CC-3D425534877DQ35106053-F49903DA-F26C-4BEF-8BF2-33C45AE6F8D4Q35210203-FFFB3DB6-290E-479A-8D34-3087394B3C18Q35915748-EAA63697-94E6-4C01-82F5-39176C28711AQ36061883-279AEBA0-BA9A-42B5-B338-E862A8AB539FQ36356537-FE4DB7B4-CF6A-46DF-A8B3-3450BE6F2E32Q36475639-D7F314F0-6036-4BAA-BE84-F0FEB471F9BAQ36475710-8647AE0E-CBEE-4D0D-9A58-55CBBA65AD59Q36510083-6D78E4A7-1F37-4E33-9767-4BF65E28C222Q36615791-7C737B03-D219-4D75-8F3F-1F575DAF814FQ36891618-81804316-83DD-4677-9003-A144A28F278DQ37064631-ADE74315-3141-4078-ADCB-502DE587E32BQ37327436-FC370B90-C800-4716-9990-41C670B4538DQ37715008-B798B246-D335-4E7B-9008-61FA0FC21626Q38528380-11146FF3-F219-46A0-BA88-361AABC3D42FQ38602815-4DFD9E14-FA40-45F4-BDCA-428B9FBB2011Q41983049-CCE86134-9231-4F85-B2F9-4B05DF0455D4Q51682614-26B9CC5E-D265-4232-A348-ECEB8A0261FBQ54981633-410C732A-DCC4-46FB-9B77-6CE1114B5341
P2860
Basic mechanisms and clinical implications of peritoneal fibrosis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Basic mechanisms and clinical implications of peritoneal fibrosis.
@ast
Basic mechanisms and clinical implications of peritoneal fibrosis.
@en
type
label
Basic mechanisms and clinical implications of peritoneal fibrosis.
@ast
Basic mechanisms and clinical implications of peritoneal fibrosis.
@en
prefLabel
Basic mechanisms and clinical implications of peritoneal fibrosis.
@ast
Basic mechanisms and clinical implications of peritoneal fibrosis.
@en
P1476
Basic mechanisms and clinical implications of peritoneal fibrosis
@en
P2093
Peter J Margetts
Philippe Bonniaud
P304
P577
2003-11-01T00:00:00Z